There were 392 press releases posted in the last 24 hours and 158,239 in the last 365 days.

CytomX to Present at the 2017 Wedbush PacGrow Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the 2017 Wedbush PacGrow Healthcare Conference.  Debanjan Ray, chief financial officer and head of corporate development will deliver a corporate overview on August 16, 2017, at 2:30 p.m. ET.

/EIN News/ -- A live audio webcast of the presentation will be available through the Investors and News section of CytomX's website. An archived replay will be available for 90 days following the event.

About CytomX Therapeutics
CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of Probody™ therapeutics. Probody therapeutics exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company’s pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc.  For more information, visit or follow us on Twitter.

Media Contact: 
Christine Quern

Investor Contact:
Trout Group
Pete Rahmer

Primary Logo

Distribution channels: Conferences & Trade Fairs, Technology